{"denoms":[{"counts":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"350"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to this arm received the study drug, tivozanib hydrochloride.","id":"BG000","title":"Tivozanib Hydrochloride"},{"description":"Participants randomized to this arm received the comparator drug, sorafenib.","id":"BG001","title":"Sorafenib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"34","upperLimit":"88","value":"62"},{"groupId":"BG001","lowerLimit":"30","upperLimit":"90","value":"63"},{"groupId":"BG002","lowerLimit":"30","upperLimit":"90","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"96"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"254"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"332"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}],"title":"Non-white"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"159"}],"title":"Two VEGFR TKIs"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"91"}],"title":"Checkpoint inhibitor plus VEGFR TKI"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"100"}],"title":"VEGFR TKI plus other systemic agent"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Previous therapies","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"70"}],"title":"Favourable"},{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"214"}],"title":"Intermediate"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"66"}],"title":"Poor"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"IMDC risk category","unitOfMeasure":"Participants"}]}